Dr. Lanny Hsieh, clinical professor of infectious diseases at UCI Health, said the FDA’s move is “very exciting.” “Putting together all of the scientific evidence we have on remdesivir to date, it remains the standard of care for hospitalized patients with COVID-19,” she said. “Ultimately, it is our patients who would benefit from this FDA approval.”
Should the FDA have approved remdesivir to treat COVID-19 patients?
Healthline, Oct. 26, 2020
October 26, 2020